Apomine - Sanofi Oncology
Alternative Names: APB-231-A2; SK&F 99085; SR-45023A; SR-9223iLatest Information Update: 10 Sep 2018
At a glance
- Originator
- Developer Sanofi Oncology
- Class Antineoplastics; Bisphosphonates; Osteoporosis therapies
- Mechanism of Action Antioxidants; Apoptosis stimulants; Bone resorption factor inhibitors; Farnesoid X-activated receptor modulators; HMG-CoA reductase inhibitors; Osteoclast inhibitors; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis; Breast cancer; Cancer metastases; Hypercholesterolaemia; Malignant melanoma; Ovarian cancer; Postmenopausal osteoporosis; Prostate cancer; Solid tumours
Most Recent Events
- 27 Aug 2018 Genzyme completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT00003822)
- 27 Aug 2018 Genzyme completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT00004049)
- 04 Feb 2008 Discontinued - Phase-I/II for Postmenopausal osteoporosis treatment in USA (PO)